Review article - Peer-reviewed, 2023
Show more authors
Application of AOPs to assist regulatory assessment of chemical risks - Case studies, needs and recommendations
Bajard, Lola; Adamovsky, Ondrej; Audouze, Karine; Baken, Kirsten; Barouki, Robert; Beltman, Joost B.; Beronius, Anna; Bonefeld-Jorgensen, Eva Cecilie; Cano-Sancho, German; de Baat, Milo L.; Di Tillio, Filippo; Fernandez, Mariana F.; FitzGerald, Rex E.; Gundacker, Claudia; Hernandez, Antonio F.; Hilscherova, Klara; Karakitsios, Spyros; Kuchovska, Eliska; Long, Manhai; Luijten, Mirjam;Show more authors
Abstract
While human regulatory risk assessment (RA) still largely relies on animal studies, new approach methodologies (NAMs) based on in vitro, in silico or non-mammalian alternative models are increasingly used to evaluate chemical hazards. Moreover, human epidemiological studies with biomarkers of effect (BoE) also play an invaluable role in identifying health effects associated with chemical exposures. To move towards the next generation risk assessment (NGRA), it is therefore crucial to establish bridges between NAMs and standard approaches, and to establish processes for increasing mechanistically-based biological plausibility in human studies. The Adverse Outcome Pathway (AOP) framework constitutes an important tool to address these needs but, despite a significant increase in knowledge and awareness, the use of AOPs in chemical RA remains limited. The objective of this paper is to address issues related to using AOPs in a regulatory context from various perspectives as it was discussed in a workshop organized within the European Union partnerships HBM4EU and PARC in spring 2022. The paper presents examples where the AOP framework has been proven useful for the human RA process, particularly in hazard prioritization and characterization, in integrated approaches to testing and assessment (IATA), and in the identification and validation of BoE in epidemiological studies. Nevertheless, several limitations were identified that hinder the optimal usability and acceptance of AOPs by the regulatory community including the lack of quantitative information on response-response relationships and of efficient ways to map chemical data (exposure and toxicity) onto AOPs. The paper summarizes suggestions, ongoing initiatives and third-party tools that may help to overcome these obstacles and thus assure better implementation of AOPs in the NGRA.Keywords
Adverse outcome pathways; Mechanistic toxicology; Hazard assessment; Regulatory risk assessment; Biomarkers of effect; New approach methodologiesPublished in
Environmental Research2023, volume: 217, article number: 114650
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE
Authors' information
Bajard, Lola
Masaryk University Brno
Adamovsky, Ondrej
Masaryk University Brno
Audouze, Karine
Institut National de la Sante et de la Recherche Medicale (Inserm)
Baken, Kirsten
VITO
Barouki, Robert
Institut National de la Sante et de la Recherche Medicale (Inserm)
Beltman, Joost B.
Leiden University
Beronius, Anna
Karolinska Institutet
Bonefeld-Jorgensen, Eva Cecilie
Aarhus University
Bonefeld-Jorgensen, Eva Cecilie
Univ Greenland
Cano-Sancho, German
Nantes Universite
de Baat, Milo L.
KWR Water Res Inst
Di Tillio, Filippo
Leiden University
Fernandez, Mariana F.
University of Granada
Fernandez, Mariana F.
Consortium Biomed Res Epidemiol and Publ Hlth CIBERE
Fernandez, Mariana F.
Instituto de Investigacion Biosanitaria IBS Granada
FitzGerald, Rex E.
University of Basel
Gundacker, Claudia
Medical University of Vienna
Hernandez, Antonio F.
Instituto de Investigacion Biosanitaria IBS Granada
Hernandez, Antonio F.
University of Granada
Hernandez, Antonio F.
CIBERESP
UKÄ Subject classification
Public Health, Global Health, Social Medicine and Epidemiology
Publication Identifiers
DOI: https://doi.org/10.1016/j.envres.2022.114650
URI (permanent link to this page)
https://res.slu.se/id/publ/120689